Menu

Early Results of First In Vivo Gene-Editing Trial Encouraging

Two patients who received Sangamo’s zinc finger–based treatment for Hunter syndrome have lower biomarkers of the condition, but no signs of new enzyme production.

Sep 5, 2018
Kerry Grens

ABOVE: The therapy targets a gene in the liver.
© ISTOCK, MAGICMINE

The first patients to have received a medium dose of a gene therapy based on in vivo gene editing have lower levels of sugar in their urine—a hopeful sign that the intervention for Hunter syndrome is working. However, clinicians did not observe an increase in levels of the enzyme they hoped to replace, Sangamo Therapeutics, which developed the treatment, reported today (September 5).

“I cannot absolutely say it’s a treatment effect,” study leader Joseph Muenzer of the University of North Carolina, Chapel Hill, tells the Associated Press. But he adds that the data are “really encouraging.” 

Hunter syndrome is a rare disease in which an enzyme deficiency leads to a buildup of complex polysaccharides. Those with the condition often die young.

See “First In Vivo Genome Editing to Be Tested in New Clinical Trial

The first person to have received the treatment got it back in November. The infusion includes a normally functioning gene for the dysfunctional enzyme and zinc finger nucleases to cut the genome and insert the gene. The treatment is targeted to the liver.

See “Man Receives First In Vivo Gene-Editing Therapy

In this latest trial, two people received a medium dose of the gene-editing reagents and two people, including the first patient, got a low dose. After 16 weeks, those who received the low dose experienced no change in their urine sugar levels. The medium-dose patients, on the other hand, saw three urine biomarkers—glycosaminoglycans, dermatan sulfate, and heparan sulfate—decline by 51 percent, 32 percent, and 61 percent, respectively.

Levels of iduronate-2-sulfatase, the enzyme targeted by the gene therapy, remained undetectable at the beginning and end of the trial’s assessments. Endpoints News reports that the result triggered a 22-percent drop in Sangamo’s stock this morning. The company says the lack of detectable enzyme doesn’t mean the gene therapy isn’t working.

“If longer-term data from this study continue to be positive, therapeutic genome editing has the potential to bring tremendous medical progress for [Hunter] and other monogenic diseases,” Edward Conner, chief medical officer of Sangamo, says in a press release sent to The Scientist.

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing